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Abstract
Based on the chemical structure and mathematical algorithm of the Prediction of Activity Spectra for Substances software, computer prediction of 
possible types of biological activity of 121 substances substituted and fused derivatives of methylxanthine, has been done.  The structure of compounds 
synthesized has been confirmed by modern physical and chemical methods: elemental analysis, UV-, IR-, HNMR- and mass-spectrometry, counter 
synthesis.  The purity of the synthesized compounds has been controlled by thin layer chromatography.  These substances are white crystalline powders, 
odorless, of a bitter taste, insoluble in water, soluble in dimethylformamide and dimethylsulfoxide and practically insoluble in alcohol, ether, chloroform, 
glacial acetic acid.  Chemical structures of tested compounds have been introduced by a computer program “Java 6 Standart Edition” and posted on the 
official site of biological spectra prediction (http://195.178.207.233/PASSNew/predsct.php) in the form of the original multi-atomic orbital descriptors 
(Multilevel Neighborhoods of Atoms).  The results of the computer prediction of the diuretic activity have been considered positive if the predicted activ-
ity probability of the substance Pa has been > 0.5.  It has been specified that the newly synthesized derivatives of methylxanthine are able to demonstrate 
the following pharmacological activities: diuretic, neurotropic, antihypoxic, analgesic, anti-inflammatory and metabolic.  By the method of computer 
prediction for substituted and fused methylxanthine derivatives it has been found that the highest diuretic activity is characteristic of the compound 
g-6713 - pyrrolidine 1,7-dimethylimidazo[1,2-f]xanthinyl acetate.  The substituted and fused derivatives of methylxanthine present a promising group 
of compounds for further synthesis and screening of new pharmacological substances with diuretic properties.
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Introduction
Currently, in the developing world new drugs screening 
is based mainly on in vitro screening of a great number of 
chemical substances having a relatively small range of bio-
logical activity. The experience in medicinal chemistry and 
experimental pharmacology does not indicate absolutely 
specific actions for the known drugs: they all cause differ-
ent pharmacological effects, some of which are used for the 
treatment of certain pathologies, and others cause side effects 
and toxicity. The full set of pharmacological effects that any 
substance has in different experimental conditions is the 
spectrum of its biological activity [1, 2].
The properties of the core structures are further opti-
mized by the synthesis and study of a large number of their 
analogues. A lot of types of biological activity specific to 
substances remain unstudied and present side effects of the 
chosen direction of the research [3].
The computer prediction is based on the assertion that the 
biological activity of the substance is a function of its chemical 
structure. In medicinal chemistry while analyzing chemical 
structure of compounds with known biological activity, the 
fragments responsible for the pharmacological effects are 
isolated, and molecules of more active and less toxic analogues 
are synthesized then [4, 5].
The PASS (Prediction of Activity Spectra for Substances) 
software is based on the analysis of “structure-activity” de-
pendence for the sample of compounds containing more than 
45000 different biologically active substances (substances of 
known drugs and pharmacologically active compounds). The 
mathematical algorithm used in the PASS software is selected 
by targeted analysis and comparison of the efficiency of a large 
number of different methods. This algorithm provides a per-
sistant type of “structure-activity” dependence and forecasts 
the results [6, 7].
The current version of the PASS software predicts 783 
types of biological activity, based on its chemical structure 
formula, using a description of the chemical structure and 
mathematic algorithm of “structure-activity” dependence, 
including main and side pharmacological effects, mechanisms 
of action, mutagenicity, oncogenicity, teratogenicity and em-
bryotoxicity [8, 9].
The results of the computer prediction are released in the 
form of a list of activities with calculated estimated probabili-
ties of activity (Pa) and the absence of each kind of activity 
(Pi), with values from 0 to 1. This probability is calculated on 
the samples of active and inactive compounds and their sum 
is not equal to 1. Pa and Pi are interpreted as the evaluation 
measures of substances belonging to the class of active and 
inactive compounds. The higher the activity for a particular 
value of Pa is and the lower the Pi value is, the greater the 
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chance to detect this activity in the experiment is. If the 
analysis of the predicted list of activities is done for the com-
pounds where Pa > 90%, we can make an assumption about 
90% actually active compounds; for Pa > 80% - only 80% of 
active compounds. The smaller Pa is, the higher the risk of a 
negative result in the experiment is, however, the originality 
of such a structure is also higher [10, 11].
One of the directions of the research in this area is a chemi-
cal modification of known physiologically active xanthines. 
The aim of the focused synthesis is to obtain more active 
analogues with increased selectivity and fewer side effects. The 
structure optimization consists of increasing the main activity 
and reducing the side effects and toxicity [8, 12].
The variety of pharmacological activities of methylxan-
thine derivatives and their high reactivity causes the relevance 
of the synthesis of new structures. The derivatives of xanthine 
are involved in the many regulation processes that occur in 
the body. In this regard, the design of the new compounds 
based on them is promising.
The aim of this work has been to make a prediction of 
biological activity spectra of synthesized substituted and 
fused derivatives of methylxanthine using the PASS software.
Connection with scientific programs, plans, themes. 
The research is performed according to the basic scientific 
plans of Kharkov Academy of Animal Health, Kaunas Medical 
University, National University of Pharmacy of Zaporozhye 
and State Medical University of Zaporozhye and is a part 
of the research on the topic “Preparation of Xenobiotics, 
Their Physical and Chemical Properties, Biological Effects 
and the Effects on Metabolic Processes” (state registration 
№ 0105U002815, ID code 15.00.02.01).
The aim of the study has been to make a computer predic-
tion of the biological activity of substituted and fused deriva-
tives of methylxanthine and establish the “structure-activity” 
dependence.
Material and methods
The objects of the study have been 121 compounds of 
substituted and fused methylxanthine derivatives, synthe-
sized by the Biological Chemistry Department, Zaporozhye 
State Medical University, under the guidance of the Doctor 
of Pharmacy, Professor Romanenko N.I.
The structure of the synthesized compounds has been 
confirmed by the modern physical and chemical methods: 
elemental analysis, UV-, IR-, HNMR- and mass-spectrometry, 
counter synthesis; the purity of the synthesized compounds 
has been controlled by thin layer chromatography. These 
substances are white crystalline powders, odorless, of a bitter 
taste, insoluble in water, soluble in dimethylformamide and 
dimethylsulfoxide and practically insoluble in alcohol, ether, 
chloroform, glacial acetic acid.
The chemical structures of the tested compounds have 
been introduced by a computer program “Java 6 Standart Edi-
tion” and posted on the official site (http://195.178.207.233/
PASSNew/predsct.php) of biological spectra prediction in the 
form of the original multi-atomic orbital descriptors (Multi-
level Neighborhoods of Atoms). The results of the computer 
prediction of diuretic activity have been considered positive 
if the predicted activity probability of the substance Pa has 
been > 0.5.
Results and discussion
Based on the chemical structure and mathematical algo-
rithm of the PASS software, the computer prediction of possi-
ble types of biological activity of 121 substances of substituted 
and fused derivatives of methylxanthine has been made. The 
prediction results are presented in table 1 in the form of a list of 
possible types of activity with calculated estimates of probable 
activity Pa and the probable inactivity Pi, with values from 
0 to 1. This algorithm has ensured obtaining the sustainable 
results based on the “structure-activity” dependence.
The analysis of the computer prediction results has showed 
that the studied derivatives of substituted and fused methylx-
anthines have a wide range of biological activity, with Pa > 0.7 
and Pi < 0.4 in most of the cases, indicating broad prognostic 
possibilities of pharmacological activity in the absence of close 
chemical analogues. At the same time, the variety of possible 
pharmacological activity implies significant non-desirable 
side effects on the human body (tab. 1).
The results of computer prediction have showed that 
substituted and fused derivatives of methylxanthines can, 
probably, show an increased urinary kidney function. So, 
for the first synthesized substances g-6237, g-4704, g-5847, 
g-5856, g-5857, g-5869, g-5871, g-7434, g-7437F, g-7435, 
g-7440, g-7441, g-7443, g-7444, g-7992, g-6492, g-6504, g-6520, 
g-4237, g-4249B, g-6387, g-6713, g-6728, g- 7964, g-7965, 
g-7966, g-7967, g-7968 the activity probability Pa has ranged 
from 0.413 to 0.815. The presence of expressed increased 
urinary renal function has also been predicted for ammonium 
salts of 1,3,7-trimethylimidazo[1,2-f]xanthinyl-8-butanoate. 
The highest factor of their diuretic activity (Pa = 0.815) has 
been predicted for the compound g-6713 – ammonium 
salt of pyrrolidine 1,7-dimethylimidazo[1,2-f ]xanthinyl 
acetate. The substitution in the 1st position of the molecule 
of 1,7-dimethylimidazo[1,2-f]xanthinyl acetate of hydrogen 
atom by the methyl radical (g-6728) reduces the probability 
of diuretic activity (Pa = 0.802). The replacing of pyrrolidine 
ammonium salt (g-6713) for morpholine (g-7963), for pip-
eridine (g-7964), for β-hydroxyethylammonium (g-7966), 
N, N-di(β-hydroxyethyl)ammonium (g-7967), diethylam-
monium (g-7968) leads to the presence of the diuretic activity. 
The blockade of A1 receptors enhances diuresis and natriu-
resis due to the inhibition of proximal tubular reabsorption 
of sodium ions. The stimulation of urinary kidney function 
is also associated with the decreased reabsorption of sodium 
in renal tubules of nephrons, accompanied by a reduction of 
the reabsorption of water and the increased urination. Most 
of these substances can be used as regulators of water and 
electrolyte balance in the body of the patient.
The peripheral vasodilator activity (Pa = 0,413-0,664) has 
also been predicted for the tested compounds, indicating the 
feasibility of using these substances to enhance distal venules 
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№ Possible activity, compounds code Ра Рі
1 Analeptic: g-6236, g-6574, g-3427, g-3428, g-3947,
g-3948, g-5847, g-5856, g-5857, g-7434, g-7435, g-7437,
g-7440, g-7441, g-7443, g-7444 
0,547-0,891 0,003-0,161
  2 Anxyolitic: g-4832, g-3842, g-3952, g-4238, g-6236, g-6237, g-6491, g-6492, g-6503,  
g-6520, g-6540, g-3825,  
g-4237, g-6369
0,252-0,358 0,051-0,091
5 Adenosine A
1
 receptor antagonist: g-6622, g-4250,
 g-3947, g-3960, g-4705, g-4706, g-4707, g-5847, g-5856, g-5857, g-5868, g-5492, g-4237, 
g-4249Б, g-6369
0,194-0,293 0,007-0,038
6 Adenosine receptors atagonist: g-4250, g-5132, g-3947, g-3960, g-6491, g-6492, g-6538, 
g-6539, g-3825, g-4237, g-4249Б, g-6369, g-6713, g-6728 
0,328-0,522 0,006-0,012
7 Adenosine A
2
 receptor antagonist: g-4250, g-3947, 
g-3960, g-6491, g-6492, g-6538, g-6539, g-6540, g-4237, g-4249Б, g-6369, g-6728
0,265-0,403 0,007-0,010
8 Alpha adreoreceptor antagonist: g-4832, g-3952, 
g-4238, g-4543, g-3961, g-4530, g-4704, g-5871, g-7992, g-7993, g-7997, g-7998, g-7999, 
g-8090, g-6540
0,080-0,209 0,029-0,060
12 Interleukin-8 antagonist: g-4853, g-5132, g-3427, 
g-3428, g-3947, g-3948, g-3960, g-4705, g-4706, g-4707, g-7839, g-7840, g-7841, g-7842, 
g-7843, g-7845, g-7846, g-8055, g-8057, g-7999
0,142-0,238 0,008-0,026
15 Antiallergic: g-4706, g-7444, g-7843, g-8057, g-7887, g-7939, g-7945, g-7967, g-7968 0,302-0,727 0,007-0,094
16 Antihistamine: g-3428, g-3952, g-6236, g-6237, g-3427, g-3428, g-3947, g-4530, g-4704, 
g-4705, g-4706, g-4707, g-5871, g-7434, g-7435
0,172-0,343 0,012-0,112
17 Antidepressant: g-4832, g-4238, g-4543, g-6236, g-6237, g-4530, g-4704, g-5863, g-5871 0,218-0,263 0,097-0,508
21 Antihypertensive: g-5847, g-5964, g-5968, g-7434, 
g-7435, g-7437Ф, g-7440, g-7441, g-7443, g-7444
0,273-0,350 0,058-0,094
22 Anti-ischemic, cerebral: g-4832, g-4835, g-4853, 
g-6622, g-3842,  g-3952,  g-4237А, g-4238, g-4249А, 
g-4543, g-6236, g-6237, g-6574, g-6575, g-6560, g-3427, g-3428, g-3947, g-4530, g-4704, 
g-4705, g-4707, g-5847, g-5871, g-7434, g-7435, g-7437Ф, g-7440, g-7441, g-7443, g-7444, 
g-7994, g-8090, g-7940
0,565-0,937 0,004-0,085
24 Sodium channel blocker: g-4832, g-4835, g-6622, 
g-3842, g-3952, g-4237А,  g-4232, g-4249А, g-4543, 
g-6575, g-6560
0,150-0,251 0,052-0,084
26 Bronchodilator: g-4835, g-4853, g-3842, g-5132, 
g-4704, g-4706, g-5847, g-7939
0,140-0,237 0,048-0,097
27 Vasodilator: g-6236, g-6237, g-3428, g-3947, 
g-4704, g-4707, g-5847, g-5871, g-7434, g-7435, g-7437Ф, g-7440, g-7441, g-7443, g-7444, 
g-7992, g-7993, g-7994, g-7995, g-7997, g-7998, g-7999,  g-8090
0,412-0,685 0,009-0,212
28 Vasodilator, coronary: g-3428, g-3947, g-4705, 
g-5847, g-5871, g-7434, g-7435, g-7437Ф, g-7440, g-7441, g-7443, g-7444, g-7940
0,413-0,664 0,010-0,112
31 Diuretic: g-6237, g-4704, g-5847, g-5856, g-5857, 
g-5869, g-5871, g-7434, g-7435, g-7437Ф, g-7440, g-7441, g-7443, g-7444, g-7992, g-6492, 
g-6504, g-6520, g-4237, g-4249Б, g-6387, g-6713, g-6728, g-7964, g-7965, g-7966, g-7967, 
g-7968 
0,413-0,815 0,003-0,112
32 Breathing analeptic: g-6236, g-6237, g-6574, g-3427, g-3428, g-3947, g-3948, g-4706, g-5847, 
g-5856, g-5857, g-5968, g-7434, g-7435, g-7437Ф, g-7440, g-7443
0,403-0,853 0,005-0,062
33 Exciting activity: g-4835, g-6622, g-3952, g-4249А, g-6236, 
g-3427, g-3428, g-3947, g-4705, g-5847, g-5857, g-5871, g-5968, g-7434, g-7435, g-7437Ф, 
g-7440, g-7441, g-7443, g-7444, g-7846, g-7992, g-7994, g-7993, g-7995, g-7997, g-7998, 
g-7999, g-8090, g-7939, g-7940 
0,513-0,878 0,008-0,238
Table 1
Analysis of the possible types of pharmacological activity for substituted  and fused derivatives of methylxanthine
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and areterioles. The reduced venous flow to the heart and 
systemic vascular resistance may contribute to reducing pre- 
and postload on the myocardium, improve the functional 
activity of the heart, reducing myocardial oxygen necessity, 
reduce blood pressure and dilate blood vessels of muscles and 
kidneys. Antihypertensive (Pa = 0,273-0,350 ), antispastic, 
papaverine-like activities (Pa = 0,231-0,389), anti-ischemic 
and cerebral (Pa=0,565-0,937) activity respectively for compo-
unds g-5847, g-5964, g-5968, g-7434, g-7435, g-7437F, g-7440, 
g-7441, g-7443, g-7444 have been predicted. For substituted 
and fused derivatives of methylxanthine the bronchodilatory 
activity (Pa = 0,140-0,237) has also been predicted.
For the tested substances g-4832, g-3952, g-4238, g-4543, 
g-3961, g-4530, g-4704, g-5871, g-7992, g-7993, g-7997, g-7998, 
g-7999, g-8090, g-6540 the alpha adrenoreceptor inhibitory 
activity has been predicted, the Pa has ranged from 0.080 
to 0.209 and the activity of vascular and breathing centers is 
increased (Pa = 0.513-0.878). For most compounds – g-4832, 
g-6622, g-3842, g-3952, g-4249, g-4237, g-4238, g-4543, g-5132, 
g-6574, g-6575, g-6560, g-6562, g-3427, g-3428, g-3947, g-3948, 
g-3960, g-3961, g-4530, g-4704, g- 4705, g-4706, g-4707, 
g-5871, g-7435, g-7992, g-7994, g-7995, g-7997, g-7998, g-7999 
– the feasibility of their use for the treatment of neurogenic 
pain has been predicted (Pa = 0.306-0.508).
The tested compounds g-4853, g-6622, g-3842, g-3952, 
g-4237, g-4249, g-6236, g-6237, g-6574, g-6560, g-3427, g-3428, 
g-3947, g-3948, g-4704, g-4705, g-4707, g-5847, g-5856, g-5857, 
g-5865, g-5868, g-7434, g-7435, g-7440, g-7441, g-7443, g-7444, 
Immunomodulatory: g-8107, g-7841, g-7845, g-7940, 
g-4237А, g-3428, g-3947, g-3960, g-4705, g-7440, g-7443, g-8104, g-8106, g-7934, g-7843, 
g-7844, g-8055, g-7887, g-7946, g-6506, g-4249Б
0,501-0,724 0,003-0,025
Immunopotentiating: g-3947, g-3948, g-4237А, g-4249А, 
g-4705, g-4707, g-6622, g-7440, g-7443, g-7841, g-7843, g-7844, g-7845, g-7846, g-7939, 
g-7940, g-8055, g-8057 
0,452-0,765 0,010-0,072
cAMP phosphodiesterase inhibitor: g-3952, g-4237А,
 g-4543, g-6236, g-6237, g-3427, g-3428, g-3947, g-3948, 
g-4530, g-4704, g-4705, g-4707, g-5847, g-5871, g-5964, 
g-5968, g-7434, g-7435, g-7437Ф, g-7440, g-7443, g-7992, g-7993, g-7997, g-7998, g-7999, 
g-8083, g-8032, g-8050,
 g-8051, g-8090, g-4237, g-6728
0,607-0,875 0,013-0,058
34 Phosphodiesterase inhibitor: g-4832, g-3842, g-3952,  g-4238, g-4543, g-5132, g-6236, 
g-6237, g-6560, g-6562, g-3960, g-4530, g-4706, g-5847, g-8033, g-8090, g-7939, 
g-7945, g-6539, g-4237, g-7968 
0,150-0,403 0,004-0,038
35 Neurogenic pain treatment: g-4832, g-6622, g-3842, g-3952, g-4249А, g-4237А, g-4238, 
g-4543, g-5132,
 g-6574, g-6575, g-6560, g-6562, g-3427, g-3428, g-3947, g-3948, g-3960, g-3961, 
g-4530, g-4704, g-4705, g-4706, g-4707, g-5871, g-7435, g-7992, g-7994, g-7995, g-7997, 
g-7998, g-7999
0,306-0,508 0,008-0,056
38 Nootropic: g-4832, g-4853, g-6622, g-3842, g-3952, 
g-4237А, g-4238, g-4249А, g-4543, g-6236, g-6237, 
g-6560, g-6562, g-4530, g-5871, g-7992, g-7993, g-7994, g-7995, g-7997, g-7998, g-7999, 
g-8024, g-8026, g-8027, g-8028, g-8029, g-8030, g-8031, g-8032, g-8051, g-8054, g-8090, 
g-4249Б
0,504-0,782 0,022-0,306
39 Peripheral vasodilator: g-6236, g-6237, g-4530, g-5847, g-5871, g-5964, g-7434, g-7435, 
g-7440, g-7437, g-7441, g-7443, g-7444, g-7992, g-7993, g-8090, g-7966, g-7967, g-7968
0,600-0,836 0,004-0,222
40 Psychogenic: g-4853, g-6622, g-3842, g-3952, g-4237А, g-4249А, g-6236, g-6237, g-6574, 
g-6560, g-3427, g-3428, g-3947, g-3948, g-4704, g-4705, g-4707, g-5847, g-5856, g-5857, 
g-5865, g-5868, g-7434, g-7435, g-7440, g-7441, g-7443, g-7444, g-8107, g-7998, g-7999, 
g-8090, g-3825, g-4237, g-6387, g-6728
0,503-0,680 0,019-0,261
41 Anti-asthmatic:  g-5132, g-6237, g-3960, g-4706, 
g-5847, g-7441, g-7444, g-7843, g-8057, g-7887, g-7939, g-7940, g-7945, g-4237, g-7969, 
g-7968
0,339-0,779 0,070-0,186
43 Antitumor: g-4835, g-3842, g-3952, g-4237А, 
g-4249А, g-4543, g-6575, g-6560, g-3427, g-3947, g-3948, g-3960, g-4530, g-4704, g-4705, 
g-4706, g-3947, g-7435, g-7434, g-7937, g-7939, g-3825
0,200-0,269 0,041-0,090
44 Anti-spasmatic, papaverine-like activity: g-4835, g-6236,
 g-6574, g-3427, g-3428, g-3947, g-3948,  g-3960, g-3961, g-4530, g-4704, g-4705, 
g-4706, g-4707, g-5856, g-5857, g-5868, g-7434, g-7435, g-7444, g-7846, g-7939, g-7943
0,340-0,696 0,004-0,041
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g-8107, g-7998, g-7999, g-8090, g-3825, g-4237, g-6387, g-6728 
(Pa = 0.503-0.680) can, probably, show a psychogenic influ-
ence on the function of the cerebral cortex and activate the 
mental and physical activities of the human body; they reduce 
reflex response time for stimulation of afferent receptors; they 
possess anxiolytic activity (Pa = 0.252-0.358), cause accelera-
tion and increased respiratory excursions (Pa = 0.403-0.853); 
they expand bronchial tubes and act as bronchodilators 
(Pa = 0.140-0.237).
According to the computer prediction data, the most 
derivatives of substituted and fused methylxanthines have 
showed antagonism to interleukin-8 (Pa = 0.142-0.238), which 
indicates the presence of anti-inflammatory and analgesic 
activity of these substances.
Most derivatives of substituted and fused methylxanthines 
inhibit the activity of phosphodiesterase (Pa = 0.150-0.403), 
which leads to the cAMP and cGMP accumulation. The anti-
histamine activity (Pa = 0.172-0.343) has also been predicted 
for the tested substances, as these substances can be used as 
antiallergic agents (Pa = 0.302-0.727) in various pathological 
conditions and allergic diseases.
The presence of antitumor activity within the range of 
Pa = 0.340-0.696 has been predicted for the following com-
pounds: g-4835, g-3842, g-3952, g-4237, g-4249, g-4543, 
g-6575, g-6560, g-3427, g-3947, g-3948, g-3960, g-4530, g-4704, 
g-4705, g-4706, g-3947, g-7435, g-7434, g-7937, g-7939, g-3825. 
They may possess an antimetabolic action and can be used to 
fight cancer diseases.
Thus, taking into account the results of the computer pre-
diction of biological activity spectra of substituted and fused 
methylxanthine derivatives using the PASS software, we have 
planned a pharmacological screening for the following types of 
pharmacological activities: diuretic, neurotropic, antihypoxic, 
analgesic, anti-inflammatory and metabolic.
Conclusions
1. By the computer prediction for substituted and fused 
methylxanthine derivatives it has been found that the highest 
diuretic activity (Pa = 0.815) belongs to the compound g-6713 
– pyrrolidine 1,7-dimethylimidazo[1,2-f]xanthinyl acetate.
2. The derivatives of substituted and fused methylxan-
thines present a promising group of compounds for the further 
synthesis and screening of new pharmacological biologically 
active substances with diuretic properties.
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